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ABSTRACT 
Ejiofor A. D. Ezekwe Jr: Cellular Mechanisms of Staphylococcus aureus α-hemolysin-
mediated Activation of the NLRP3 Inflammasome 
(Under the direction of Joseph Duncan) 
 
Background: 
Staphylococcus aureus toxin, α-hemolysin, is secreted as a soluble monomer that forms 
a heptameric pore in the membranes of a range of host cell types. Hemolysin binds and 
activates A Disintergin and Metalloprotease 10 (ADAM10) and is a well-chronicled 
virulence factor in staphylococcal disease. ADAM10 activity is important for toxin-
mediated pathology in a number of cell types. In host monocytes, α-hemolysin activates 
the nucleotide-binding domain and leucine-rich repeat containing gene family, pyrin 
domain containing 3 (NLRP3) inflammasome leading to production of the pro-
inflammatory cytokines (IL-1β, IL-18) and pyroptotic cell death. Human airway epithelial 
cells express the components of the NLRP3 inflammasome but the involvement of this 
signaling pathway in the cellular response to α-hemolysin is unknown. We hypothesized 
that both ADAM10 and NLRP3 are involved in host cellular responses to α-hemolysin in 
both monocytic and respiratory epithelial cells.  
Methods:  
To elucidate the role of ADAM10 and its protease activity in α-hemolysin-mediated 
activation of the inflammasome, we used the immortalized monocyte cells line, THP1 
and U937. Cells were treated with siRNA against or chemical inhibitors of ADAM10, 
 iv		
challenged with α-hemolysin, and NLRP3-inflammasome activation assessed by 
measuring secreted IL-1β, cell death, and activation of caspase-1. 
To test for evidence of α-hemolysin-mediated inflammasome activation in respiratory 
epithelial cells, we used primary human tracheobronchial epithelial (hTBE) cells and 
measured their secretion of IL-1β in response to hemolysin challenge.  
Results:  
Loss of ADAM10 cell surface expression led to diminished α-hemolysin-mediated 
activation of the NLRP3 inflammasome and cell death. ADAM10 protease activity, 
however, was not required for NLRP3 activation in human monocytes. hTBEs secrete 
mature IL-1β in response to α-hemolysin treatment, suggesting a role for the 
inflammasome in their response to α-hemolysin. 
Conclusions:   
This work demonstrates that ADAM10’s receptor and not its protease activity, is 
important for inflammasome activation by α-hemolysin in human monocytes. Preliminary 
evidence also suggests that the inflammasome may play a role in epithelial cell 
responses to α-hemolysin. 
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CHAPTER ONE: Introduction 
 
Innate Immunity and the NLRP3 inflammasome: 
The innate immune system is one of the major functional barriers against 
infection. This system utilizes gene encoded pathogen recognition receptors (PRRs) to 
sense and respond to danger signals external and internal to the cell. PRRs are critical 
to the proper function of the innate immune system and are evolutionarily conserved 
across a wide array of organisms from Drosophila to human [1-5]. Although immune 
cells of hematopoietic origin tend to express the widest array of PRR, most cell types 
express some PRRs allowing innate immune responses to be initiated at sites of 
invading microorganisms. These receptors respond to a broad array of stimuli, which 
have been termed danger-associated molecular patterns (DAMPs) and pathogen-
associated molecular patterns (PAMPs). Some of the molecular pattern recognized by 
PRRs include lipids (e.g. lipopolysaccharide from gram-negative bacteria), proteins (e.g. 
porins from Neisseria species), bacterial cell wall components (e.g. peptidoglycan), 
nucleic acids (e.g. bacterial and viral DNA and RNA), and carbohydrates (e.g. Mannan 
from candida albicans) [2, 6].  PRR activation by DAMPS or PAMPS leads to a number 
of different cellular responses that have evolved to curtail pathogen invasion or 
replication including: production of cytokines that recruit cells of the immune system as 
well as induce programs of antimicrobial response, production of antimicrobial peptides, 
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priming of the adaptive immune system, production of reactive oxygen species, 
autophagy to contain pathogens and even programed cell death to contain infections 
and promote inflammation [2, 4, 6-11]. 
In mammals, there are many signaling proteins that fall under the umbrella of 
PRRs including Toll-like receptors (TLRs), retinoic acid-inducible gene (RIG)-I-like 
receptors (RLRs), c-type lectins receptors (CLRs), and the Nod-like receptor (NLRs) 
proteins [11, 12]. The macromolecular structure known as the inflammasome is an 
effector mechanism common to several innate immune signaling pathways. The 
canonical inflammasome acts as platform for the activation of the cysteine proteinase, 
Caspase-1.  Inflammasomes utilize a number of different PRR as sensors to initiate 
Caspase-1 activation. PRRs that can serve as the sensor components for the 
inflammasome include: AIM2 (absent in melanoma 2; a cytosolic dsDNA sensor) [13] 
and a number NLR family members including NLRP3 [4, 7, 14-16]. Caspase-1 
activation leads to the processing, and release of the cytokines IL-1β and IL-18 [3, 4, 8, 
17]. Inflammasome activation also leads to a form of inflammatory cell death termed 
pyroptosis [3, 18-20]. Pyroptosis is defined by being initiated by the pro-inflammatory 
caspases-1 and 11 leading to pore-formation in the cellular membrane and permeability 
to small molecular weight dyes. This leads to cell lysis due to the influx of water and 
ions and release of pro-inflammatory mediators such as HMGB1 (High mobility group 
box 1) [19-21]. Pyroptosis differs from apoptosis, a non-inflammatory pathway of 
programmed cell death, in a number of ways. Pyroptosis does not lead to the 
characteristic internucleosomal cleavage of DNA seen in apoptosis caused by activation 
of CAD (caspase-activated DNase). Apoptosis is also non-lytic, with intracellular 
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contents being contained within membrane bound apoptotic blebs, while pyroptosis is 
marked by lytic activity leading to cell swelling, rupture, and release of intracellular 
contents. Finally, the inflammatory caspases-1 and 11 cause pyroptosis, while 
apoptosis is executed by caspases-3 8, 9 and 10 [19, 20]. Downstream of caspase-1 
activation is gasdermin D, a caspase-1 and caspase-11 substrate, which upon cleavage 
can induce cell death. Loss of gasdermin D greatly diminishes pyroptosis and the N-
domain alone is enough to cause pyroptosis. The effector mechanisms leading to death 
downstream of gasdermin cleavage by caspase-1 are yet to be identified [22-24]. 
NLRP3 (Nucleotide-binding domain and Leucine-Rich repeat containing family 
Pyrin domain containing 3) was one of the first PRR sensors found to cause 
inflammasome formation. NLRP3 is a member of the NLR family of proteins, which are 
defined by a conserved three domain structure; a leucine-rich repeat domain, a 
nucleotide binding domain, and an N terminal effector domain [7, 14, 25]. The N 
terminal effector domain of NLRP3 is the pyrin domain. During inflammasome 
assembly, the pyrin domain of NLRP3 associates with the pyrin domain of the adapter 
molecule, ASC (apoptosis-associated speck-like protein containing a caspase 
recruitment domain). The oligomerization of ASC with NLRP3 is thought to initiate a 
cascade of self-propagating ASC pyrin-ASC-pyrin associations leading to assembly of 
large macromolecular fibrils.  Caspase-1 is recruited to this structure via CARD-CARD 
domain interactions between the C-terminal CARD domain of ASC and the amino 
terminal CARD domain of pro-Caspase-1. This super structure allows for pro-caspase-1 
to cluster and brings caspase domains in proximity to allow for auto-cleavage and 
activate the protein [26-28].  
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While many NLRs are activated by specific stimuli, NLRP3 is activated by a 
broad range of DAMPs and PAMPS including extracellular ATP, alum, uric acid, and 
bacterial pore-forming toxins [17, 18, 29, 30]. In humans, NLRP3 mutations lead to the 
development of a group of autoinflammatory diseases termed cryopyrin-associated 
periodic fever syndromes including disease like Muckle-wells syndrome and familial 
cold autoinflammatory syndrome [31, 32]. These diseases have a spectrum of severity 
and are associated with periodic fevers, rashes, conjunctivitis, and arthralgias [32]. 
These diseases can often be treated with IL-1β blocking therapies. While it is not fully 
elucidated as to how these diverse sets of stimuli are encoded into NLRP3 activation, 
there are some general mechanisms that are thought to be important for NLRP3 
inflammasome activation. These include potassium efflux, reactive oxygen species 
(ROS) based signaling and lysosomal destabilization [30, 33]. Potassium efflux has 
been strongly associated with inflammasome activity as increased extracellular K+ or 
chemical inhibition of K+ efflux have been shown to strongly inhibit NLRP3 activation in 
response to a broad range of activating agents including ATP and pore-forming toxin 
[28, 34, 35]. ROS has also been implicated in NLRP3 activation as use of ROS 
chemical scavengers and inhibition of NADPH oxidase activity have both been shown to 
block inflammasome activation in response to ATP and particulate matter including 
silica and asbestos [33, 36, 37]. Thioredoxin-interacting protein (TXNIP) has also been 
shown to bind the NLRP3 inflammasome in a ROS dependent manner in response to 
NLRP3 activating stimuli including uric acid crystals [38]. Interestingly, oxidized 
mitochondria DNA has also been shown to bind and activate the NLRP3 and inhibition 
of this process greatly diminishes inflammasome activation in response to ATP, the 
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pore-forming toxin nigericin, and alum [39]. Finally, there is strong evidence for the role 
of lysosomal destabilization in the activation of the NLRP3 inflammasome. It was 
discovered that lysosomal damage induced by NLRP3 activation factors such as uric 
acid crystals and silica leads to lysosomal disruption and leakage of lysosomal contents 
[40]. Chemical blockade of this process or treatment of cells with inhibitors of lysosomal 
proteases like cathepsin B can diminish inflammasome activation in response to those 
activating stimuli [30, 33]. Lysosomal destabilization has also been found to be an 
important mechanism for inflammasome activation in the context of bacterial infections 
as blockade of lysosomal acidification, phagocytosis or cathepsin B have all been 
shown to reduce NLRP3 activation in response to Group B streptococcal infection and 
Streptococcus pneumonia toxin pneumolysin [41, 42]. 
Bacteria often produce a number of virulence factors that use one or more of 
these pathways to activate the NLRP3 inflammasome [43]. Staphylococcus aureus is 
one such pathogen that is a major public health challenge and has multiple mechanisms 
by which it activates the inflammasome.  
 
Staphylococcus aureus and its role in human disease:  
Staphylococcus aureus is a gram-positive pathogen that is a major cause of 
morbidity and mortality in both hospital and community settings [44-46]. The bacterium 
is ubiquitous in our environment and a significant proportion of the population (about 20-
30%) carry S. aureus primarily in their noses but the bacterium can colonize other parts 
of the body including the axillae, vagina, pharynx and skin [46-51]. Carriage of S. 
aureus is a risk factor for infection with the bacterium [48-51]. S. aureus is primarily 
 		 6	
spread by skin to skin contact with a carrier or by contact with contaminated surfaces. 
S. aureus is capable of causing infection in normal healthy hosts but there a number of 
conditions that can lead to increased susceptibility to infection.  This is particularly the 
case in conditions where the epithelial barrier is disrupted like traumatic injury, 
surgeries, or insertion of medical devices [45, 46, 52]. Additionally, patients with 
compromised granulocyte function through genetic conditions like CGD (chronic 
granulomatous disease) or through administration of leukoablative chemotherapy have 
increased risk of invasive S. aureus infection [53]. Finally, S. aureus has the capacity to 
form biofilms in invasive infection that can lead to prolonged and difficult to treat 
infections. Biofilms are most likely to be formed on non-biologic substances such as 
prosthetic joints and intravenous catheters [46, 54].  The bacterium is also capable of 
establishing niches in both the household and community settings by persisting on 
surfaces and being successfully transmitted from person to person, allowing for its wide 
dissemination from public places to the home and back again. This allows for 
continuous spread that may serve as a key sources for recurrent infections [55].  
Due to the emergence of resistant strains like Methicillin Resistant 
Staphylococcus aureus (MRSA) the bacterium is becoming a serious public health 
challenge [44, 46, 56-58]. S. aureus was initially susceptible to penicillin but resistance 
to the drug resulted from acquisition of a betalactamase. This resistance soon became 
widespread.  Oxacillin, methicillin and several other penicillin-derived drugs resistant to 
beta-lactamase were used effectively for many years [59]. Methicillin resistance resulted 
from acquisition of a PBP2A, a penicillin binding protein that does not bind methicillin or 
related penicillins and was first found a year after the introduction of methicillin in 1961 
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[46, 60]. Methicillin resistance was initially only found in S. aureus from hospital 
acquired strains that persisted in patients who were highly exposed to antibiotics. Then 
MRSA became widespread by the 1970s [60, 61]. Once mainly an issue in hospitalized 
patients, community-acquired MRSA (CA-MRSA) infections have been on the rise and 
often cause infections in previously healthy individuals [56-58]. This spread of antibiotic 
resistance has led to a need to better understand pathogenesis and develop novel 
therapeutic strategies 
S. aureus is capable to causing serious infections in numerous tissue types 
including skin and soft tissues, bone, blood, and the lungs [45, 46, 62]. S. aureus skin 
infection is often characterized by the formation of abscesses but can lead to cellulitis, 
or in the most severe cases necrotizing fasciitis which can lead to tissue destruction and 
limb loss. In many communities across the United States MRSA is the most common 
cause of skin and soft tissue infections [63]. Treatment of S. aureus skin infections often 
includes lancing and drainage of abscesses in additional to treatment with oral 
antibiotics [56, 63]. Due to the prevalence of MRSA in skin infections beta-lactam 
antibiotics are no longer recommended for treatment of staphylococcal skin infections. 
So severe skin infections are often treated with more powerful antibiotics like parenteral 
vancomycin and linezolid [62, 64]. 
S. aureus is also the major causative agent in bone infection (osteomyelitis) and 
joint infections (infectious arthritis) [65, 66]. This can occur either through the spread of 
infection from surrounding tissue like skin and soft tissue or through the circulatory 
system due to S. aureus bacteremia [62]. The main risk factors for osteomyelitis include 
age, history of injection drug use, immunosuppression, or diabetes mellitus [52]
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staphylococcal osteomyelitis is difficult to treat requiring prolonged antibiotic courses of 
greater than 8 weeks to clear the infection [52]. If the infection affects artificial joints a 
debridement and implant retention procedure is used in conjunction with antibiotic 
treatment to save the implant [67, 68]. In many cases, S. aureus prosthetic joint 
infection is treated with prosthesis removal followed by prolonged antibiotic therapy. A 
new prosthetic joint replacement can be inserted after therapy [69]. 
Bacteremia is another major infection often caused by S. aureus. Bacteremia can 
lead to seeding of other sites, causing infections, particularly abscesses, in other parts 
of the body. Intravenous devices including catheters, pacemakers, defibrillators, and 
grafting materials used in revascularization procedures all pose serious risk for 
development of S. aureus bacteremia [45, 62]. Some other risk factors associated with 
S. aureus bacteremia are injection drug use due to inoculation of bacteria from 
contaminated skin, and hemodialysis because of the prolonged need for IV 
catheterization [44]. S. aureus bacteremia can have high rates of mortality ranging from 
10-30% and mortality is often affected by the age and health status of the patient [70]. 
Patients often require as least two weeks of antibiotic treatment for uncomplicated 
infections and much longer treatment durations for patients with complicated disease 
like patients with ongoing disease of the heart valves [62, 71].  
S. aureus is also an important causative agent of pneumonia in both the hospital 
and community settings, being among the top causative agents in hospital acquired 
infections [72-75]. Health-care associated S. aureus infection tends to affect elderly 
patients with multiple underlying diseases and often a history of ventilator use. This can 
lead to bacteremia, which is associated with poor outcomes [76, 77]. Community-
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acquired pneumonia can often present as a superinfection after flu or other viral 
infections and lead to severe disease in previous healthy patients [78-80]. This was 
thought to be a major cause of deaths during the 1918 Flu pandemic [81]. A subset of 
patients with MRSA pneumonia can develop the life-threating complication of 
necrotizing pneumonia, which is associated with coughing up blood (hemoptysis), acute 
respiratory distress, pleural effusion and leukopenia. Additionally, strains that produce 
the Panton-Valentine toxin are associated with increased incidence of necrotizing 
pneumonia [81-84].   
 
Staphylococcus aureus α-hemolysin: Structure, Function and Pathogenesis: 
S. aureus has a number of virulence factors that are important for promoting its 
pathogenesis. These include exotoxins, immunomodulatory proteins, and protective 
factors that improve resistance to immune-mediated killing [45, 46].  S. aureus 
generates an array of exotoxins that damage or compromise host cell membranes. 
Many of these toxins are secreted as subunits that assemble into beta barrel pores in 
host cell membranes. Most S. aureus beta-barrel, pore-forming toxins are assembled 
from two different protein subunits and have been termed bicomponent leukotoxins [85].  
However, the S. aureus toxin, alpha hemolysin (or alpha-toxin) forms beta-barrel pores 
from a single subunit, encoded by the hla gene [86]. These pore forming toxins are 
recruited to host target cells by high affinity toxin receptors on the host cell surface. The 
range of host cells affected by each toxin is dictated by the repertoire of toxin receptors. 
These toxin receptors tend to be host cell membrane proteins with tissue specific 
expression [85, 87, 88]. 
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α-hemolysin (Hla) or alpha-toxin is one of the best-studied pore-forming toxins. 
Studies pointing to the hemolytic activity of S. aureus α-toxin have been on going for 
much of the last century. α-hemolysin’s contributions to pathogenesis were first 
thoroughly explored after a vaccination incident in which several children died after 
exposure to a diphtheria toxin-anti toxin vaccination contaminated with S. aureus [86]. 
The authors described the hemolytic and dermatonecrotic activity of S. aureus 
supernatants upon injection into rabbits and postulated the existence of a single factor 
being responsible for the observed biological effects [89, 90]. Hla was later isolated and 
it was postulated the toxin mediated cellular damage by disrupting host cell membranes 
[91]. This conclusion was supported by the speed of cell lysis and leakage of low 
molecular weight markers including alpha-aminoisobutyric acid seen upon Hla 
intoxication of susceptible cells, and the presence of pore-like structure in the 
membrane of intoxicated cells [86, 92-94].  Not all cells are equally sensitive to Hla 
intoxication and early in vitro studies models of Hla intoxication used rabbit erythrocytes, 
which are highly sensitive to toxin treatment [95, 96]. Interestingly, human erythrocytes 
are comparatively more resistant to Hla intoxication while other human cell types 
including platelets and monocytes are highly sensitive [97, 98]. Hla production by the 
bacterium is regulated by the accessory gene regulator (agr) locus through the 
regulatory RNA molecule, RNA III that becomes active during the late-log and stationary 
phases of growth [99, 100]. This ties the highest production of Hla to the late-
log/stationary phase of bacterial growth in culture. The Sae and Sar regulatory systems 
also play a role in Hla regulation. Sae regulates Hla transcription and Sar regulates Hla 
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production by enhancement of agr activity but can also promote Hla production in an 
agr independent fashion [101-103]. 
Hla is β-barrel pore-forming toxin that is secreted as a soluble monomer, which 
oligomerizes and forms a heptameric pore in the membranes of intoxicated cells [94, 
104]. The assembled toxin has three distant structural motifs, the cap domain which is 
the externally facing portion of the toxin, the rim domain which interfaces with the 
external portion of the membrane, and the stem domain which is the structure that 
spans the width of the membrane [105]. The pores formed by these structures are 
approximately 1-3 nm in size and allow for the passage of molecules between 1 to 4 
kDa in size [94]. There are a number of factors that have been shown to be important 
for Hla binding to host cell membranes. These include the presence of cholesterol as 
cholesterol depletion leads to decreased Hla binding and phosphocholine head group 
as depletion of the phosphocholine head groups with sphingomyelinase also greatly 
diminishes toxin binding [106]. Additionally, it was recently discovered that Hla binding 
to the cell surface metalloprotease ADAM10 (A Disintegrin and Metalloprotease 10) 
mediates the aforementioned differences in cell type sensitivity to the actions of the 
toxin [107]. There is a strong correlation between ADAM10 expression and susceptibility 
to Hla-mediated cytolysis. Loss of ADAM10 in cells blocks Hla’s ability to bind and lyse 
cells, and ADAM10 is pulled down with Hla in intoxicated cells [107].  
Hla is widely expressed in clinical isolates of S. aureus and is thought to be a 
critical virulence factor in human disease [86]. There are several studies in humans 
showing an association between anti-Hla antibody titers and protection from S. aureus 
infection [108-110]. One study in adults with high sepsis risk showed that higher 
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antibody titers to S. aureus exotoxins including α-hemolysin reduced their risk of 
disease [109]. In a second study completed in children, patients with invasive skin 
infection developed high anti-Hla titers and after a one-year follow-up, children that 
maintained high anti-Hla titers were protected from recurrent disease [108]. α-hemolysin 
is also a critical virulence factor in mouse models of disease [111-115]. In studies that 
compare α-hemolysin secreting S. aureus strains to mutant strains devoid of hemolysin 
secretion, numerous models show decreased pathogenesis. This decreased 
pathogenesis has been seen in models of S. aureus pneumonia [111-113], peritonitis 
[116, 117], skin infections [115, 118], corneal infections [119], endocarditis [120] and 
mastitis [121, 122]. In mouse models of S. aureus pneumonia, the loss of Hla 
production leads to stark reductions in the ability of the bacterium to cause lethal 
disease [111, 112]. In mouse models of S. aureus peritonitis, loss of Hla expression and 
active or passive immunization against Hla led to dramatically reduced lethality but not 
abscess formation cause by bacterial infection [116, 117]. In S. aureus skin infection 
loss of Hla expression or immunization of mice against Hla lead to reductions in 
dermonecrosis caused by S. aureus and reduction in the size of lesions at the site of 
infection [115, 118]. Corneal S. aureus infection in a rabbit leads to damage and 
inflammation marked by epithelial erosions some of which could be replicated by 
treatment of rabbits with Hla alone. Loss of Hla expression in S. aureus corneal 
infecting strains led to decreased corneal damage and the absence of epithelial 
erosions [119]. In a model of rabbit endocarditis, loss of Hla expression lead to 
decreased pathology marked by low levels of intravegetation staphylococcal densities 
as compared to parental strains with normal levels of Hla production [120]. In a mouse 
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model of S. aureus mastitis, loss of Hla expression led to decreased mortality, reduced 
invasion and lesser lesions than after infection with Wild-type strains [121].   All these 
studies illustrate the importance of Hla in reducing disease severity and mortality in 
animal models of infection.  
An important component in α-hemolysin mediated pathogenesis is it ability to 
induce immune activation in leukocytes. It was first discovered in the late 1980s that Hla 
intoxication of human monocytes led to secretion of IL-1β [97]. Hla has now been shown 
to activate the NLRP3 inflammasome in human and murine monocytes and neutrophils 
leading to IL-1β secretion and NLRP3 dependent cell death [123-125]. This activation is 
dependent on K+ efflux as high extracellular levels of K+ diminish NLRP3 dependent IL-
1β secretion and cell death [123, 125]. The consequences of Hla-mediated NLRP3 
activation are complex and can have both positive and negative outcomes. In murine 
models of S. aureus pneumonia NLRP3 inflammasome activation is deleterious to the 
host [124]. Mice lacking NLRP3 showed decreased lung pathology, decreased IL-1β 
secretion in the lung and decreased mortality from pneumonia when treated with either 
Heated Killed Staphylococcus aureus + Hla or whole bacteria capable of secreting Hla. 
Additionally, loss of NLRP3 in this setting did not affect the bacterial burden or disease 
clearance in these mice [124]. Alternatively, in the skin diminished IL-1β signaling, 
which was shown to be NLRP3 and ASC dependent, leads to decreased bacterial 
clearance and increased lesion size [126]. More recent studies in mice have confirmed 
the importance of Hla activity on immune cells in mouse models of disease in 
determining disease outcome. Loss of the cell surface receptor for Hla, ADAM10 (A 
Disintegrin and Metalloprotease 10), in cells of the myeloid linage led to exacerbation of 
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skin infection but decreased severity of pneumonia caused by S. aureus [127]. Mice 
with loss of ADAM10 expression in cells of the myeloid lineage saw increased skin 
abscess size, dermonecrosis, and increased bacterial burden in their lesions. In a S. 
aureus pneumonia model, loss of ADAM10 expression in myeloid cells, reduced 
mortality caused by the bacterial infection. These finding were attributed to decreased 
inflammatory signaling as loss of ADAM10 led to defects in the ability of ADAM10-/- 
macrophages and neutrophils to produce IL-1β in response to treatment with Hla [127].
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CHAPTER TWO: ADAM10 Cell Surface Expression but Not Activity is Critical for 
Staphylococcus aureus α-Hemolysin-Mediated Activation of the NLRP3 
Inflammasome in Human Monocytes 
 
2.1 Introduction: 
Staphylococcus aureus is a gram-positive bacterium that is responsible for 
causing infections that lead to severe morbidity and mortality. S. aureus causes 
infections in a broad range of host tissues including the skin, vascular, and respiratory 
systems[45]. It is also a growing public health concern because of the emergence of 
antibiotic resistance including methicillin resistant strains that cause both hospital and 
community acquired infections [58, 82, 128].  
Staphylococcus aureus produces an array of virulence factors that are important 
for the pathogenesis of infections caused by these bacteria. Among these virulence 
factors are several pore-forming toxins that attack host cells by permeabilizing their cell 
membranes. The pore-forming toxin, α-hemolysin (Hla) is one of the best studied of 
these factors and is critical for virulence in mouse models of infections caused by S. 
aureus[86, 111, 112, 115]. Hla is active against cells from a variety of tissues including 
respiratory epithelium, endothelium, immune cells, and keratinocytes [86]. This broad 
range of cellular targets stems from the nearly universal expression of the host cellular 
receptor for Hla, A Disintegrin and Metalloproteinase-10 or ADAM10 [107]. Additionally, 
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the level of ADAM10 expression on a given cell type dictates sensitivity to the toxin 
[107]. Genetic loss or chemical inhibition of ADAM10 protects cellular targets from Hla 
in tissue culture and mitigates Hla-induced pathology in mice [107, 127, 129-132]. 
Further, mice treated with ADAM10 inhibitors or with tissue specific knock out of 
ADAM10 exhibit resistance to S. aureus infection. In epithelial and endothelial cells, 
Hla’s interaction with ADAM10 leads to the activation of ADAM10’s metalloproteinase 
activity. This enhanced protease activity leads to the cleavage of cell surface adhesins, 
like E-cadherin, and disruption of cell-to-cell contacts [107, 131]. Consequently, it is 
believed that activation of ADAM10 by Hla is important for S. aureus ability to penetrate 
epithelial and endothelial barriers and thus cause invasive infection.  
Hla is also a potent activator of the innate immune signaling protein, Nucleotide-
binding domain and Leucine-Rich repeat containing family Pyrin domain containing 3 
(NLRP3) inflammasome [123, 125]. The active NLRP3 inflammasome is a protein 
complex containing NLRP3 and the apoptosis-associated speck-like protein containing 
a caspase recruitment domain (ASC) which is responsible for activation of the cysteine 
proteinase caspase-1. Active caspase-1 then goes on to proteolytically process the 
cytosolic, pro-inflammatory cytokines pro-IL-1β and pro-IL-18 into their active, secreted 
forms [133, 134]. In addition, NLRP3 activation leads to a program of necrotic cell death 
termed pyroptosis [134-136]. Mice with genetic deletion of Nlrp3 have diminished 
inflammation in Hla-induced pneumonitis models and decreased severity of infection in 
a mouse model of Staphylococcal pneumonia [124].  Conversely in murine models of S. 
aureus skin infection IL-1β production is important for proper bacterial clearance [126, 
127]. In this study, we sought to determine the role of Hla induced ADAM10 activation in 
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the NLRP3 inflammasome signaling pathway. We show that in human monocytes 
ADAM10 mediates NLRP3 activation and that the level of ADAM10 cell surface 
expression and not its protease activity, is important for NLRP3 activation.
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Materials and Methods:  
siRNA transfection of THP1 cells: 
THP1 cells were purchased from ATCC (Manassas, VA, USA). THP-1 cells were 
maintained in RPMI 1640 media (Gibco, Thermo Fisher Scientific, Waltham, MA. USA) 
supplemented with 10% Fetal calf serum and Penicillin and Streptomycin as described 
in prior studies [123, 137]. Cells were transfected with the TransIT-TKO® transfection 
reagent from Mirus (Madison, WI, USA) per the manufacturers protocol (product #: MIR 
2150). Cells were transfected with 50nM of pooled siRNA constructs in 6 well plates. 
siRNAs were obtained from the GE/Dharmacon (Lafayette, CO, USA) siGENOME 
library. A set of 4 siRNA was ordered for both ADAM10 (product #: D-004503-01-0002, 
D-004503-03-0002, D-004503-04-0002, D-004503-05-0002) and NLRP3 (product #:D-
017367-01-0002, D-017367-02-0002, D-017367-03-0002, D-017367-04-0002) and 
pooled prior to transfection. Control siRNA used, include Lamin A/C (product #: D-
001050-01-05), and a pool of non-targeting siRNA (Non-targeting siRNA 2, 4, and 5) (#: 
D-001210-02, D-001210-04, D-001210-05), were ordered from GE/Dharmacon 
(Lafayette, CO, USA) as well. Cells were incubated for 3 days after transfection prior to 
use in subsequent experiments.  
Immunoblots analysis:  
Westerns were performed as done by Craven et al.[123] Primary antibodies used 
were Adipogen Life Sciences (San Diego, CA, USA) anti NLRP3 monoclonal antibody 
(#:AG-20B-0014-C100) and ABCAM (Cambridge, MA, USA) anti-ADAM10 rabbit 
polyclonal (#: ab1997). Blots were imaged using a FluorChem E system from 
ProteinSimple (San Jose, CA, USA) 
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Treatment of Cells with inhibitors: 
GI254023x was purchased from TOCRIS Bioscience (Bristol, UK) (product #: 
3995) or Sigma (St. Louis, MO, USA) (product #: SML0789) and resuspended in DMSO 
to either 10 mM or 20 mM stocks. TAPI2 was purchased from Enzo Life sciences 
(Farmingdale, NY, USA) (product #: BML-PI135-0001) or Sigma (St. Louis, MO, USA)  
(product #: SML04020) and resuspended in pyrogene free water to 10mM. Cells were 
then treated with vehicle or inhibitor as indicated prior to challenge with inflammasome 
activating stimuli. 
Treatment of cultured cells with inflammasome activators for cytokine studies: 
THP-1 and U937 cells were suspended in RPMI 1640 media (Gibco, Thermo 
Fisher Scientific, Waltham, MA. USA) supplemented with 10% fetal calf serum and 
Penicillin and Streptomycin at 1x106 cells/mL and plated in tissue culture treated 24 or 
48 well plates. U937 cells were treated overnight with phorbol 12-myristate 13-acetate 
(PMA) (Sigma, St. Louis, MO, USA product #: P1585). When indicated, the NLRP3 
inflammasome was primed in the cells by treatment with E. coli lipopolysaccharide 
(Invivogen, product #: tltl-3pelps) at a concentration of 100ng/ml for 3 hours. 
Recombinant α-hemolysin prepared as described by Craven et al. [123], α-hemolysin 
(30 µg/mL) for THP1 cells or (10 µg/mL) for U937 cells, Nigericin (50µM) (Sigma, St. 
Louis, MO, USA product #: P1585), or ATP (5 mM) was added at the indicated 
concentrations to induce NLRP3 inflammasome activation. After 1 hour, Cells and 
supernatants were collected by centrifugation at 17000 x g for 3 minutes. Cell culture 
supernatants were stored frozen at -80°C until assayed for cytokine content.  LDH 
activity was measured in supernatants using the Cyto-tox ONE kit (Promega, Madison, 
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WI, USA, product #: G7891) read on a Perkin Elmer inspire plate reader. IL-1β was 
measured in cell culture supernatants using either Perkin Elmer Alphalisa (Product #: 
AL220C, Waltham, MA, USA) or BD bioscience (product #: 557953, San Jose, CA, 
USA) ELISA kits as per manufacturer protocols.  
Treatment of cultured cells with inflammasome activator for cell death studies: 
Cells were suspended in fresh media at 1x106 cells/mL and plated in tissue 
culture treated 24 or 48 well plates.  Recombinant α-hemolysin was prepared as 
described by Craven et al.[123] Cells were treated with α-hemolysin (30µg/ml) or 
Nigericin (50µM) at the indicated concentrations to induce NLRP3 inflammasome 
activation. After 1 hour, Cells and supernatants were collected by centrifugation at 
17,000 x g for 3 minutes. Prior to the end of the experiment a control group of cells were 
lysed using 1% Triton X-100 as a lysis control. Cell culture supernatants were stored 
frozen at -80°C until assayed for LDH production. 
Propidium Iodide studies: 
Cells were suspended in fresh media at 1x106 cells/mL and plated in tissue 
culture treated 48 well plates at 300 µL per well. Propidium Iodide was added to cells 5 
minutes prior NLRP3 activating stimuli, α-hemolysin (30 µg/ml) or Nigericin (50 µM). 
Cells were incubate for 1 hour prior to cells being washed once with PBS and fixed 
using BD stabilizing fixative (product #: 338036, San Jose, CA, USA). Cells were then 
assayed by flow cytometry for Propidium iodide staining on a BD accuri C6 flow 
cytometer (San Jose, CA, USA). 
Measurement of caspase-1 activity in treated cells: 
Caspase-1 activity was measured using the FLICA® 660 caspase-1 assay kit, 
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far-red fluorescence (Product #: 9122) from ImmunoChemistry Technologies LLC 
(Bloomington, MN, USA). Cells were plated in a 48 well at 300 µL per well at 1x106 
cells/ml. The FLICA reagent was added and incubated with cells for 15 minutes prior to 
the addition of the indicated inflammasome activator, α-hemolysin (30 µg/ml) or 
Nigericin (50 µM). Cells were then incubated for an additional 30 minutes, transferred to 
1.5 ml tubes, and washed twice with PBS. Cells were resuspended in 300 µl of PBS and 
50 µL of supplied fixative. Accumulation of fluorescent caspase-1 inhibitor was assayed 
by flow cytometry on a BD accuri C6 flow cytometer (San Jose, CA, USA) 
Measurement of ADAM10 cell surface immunofluorescence staining protocol: 
siRNA transfected cells were resuspended in 2% BSA in 1x PBS with 0.1% 
sodium azide at a concentration of 1x107 cells/ml. One-hundred microliters of cells were 
added into sterile tubes with 5ul of either PE mouse IgG1, κ Isotype control Ab from 
Biolegend (San Diego, CA, USA) (product #: 400113) or PE anti-human CD156c 
(ADAM10) from Biolegend( product #: 352703). Cells were incubated with antibodies for 
15-20 minutes in the dark at 4°C. Cells were then twice washed with 2mL of buffer and 
spun down at 350 G for 5 minutes. Cells were resuspended in 500 µl of buffer prior to 
being analyzed by flow cytometry on a BD accuri C6 flow cytometer (San Diego, CA, 
USA). 
In the inhibitor time course assays cells were resuspended in fresh RPMI media 
at a concentration of 1x106 cells/ml. Cells were plated at 300 µl per well in a 48 well 
sterile tissue culture treated plate. Inhibitors and vehicle controls were added at the 
indicated times after which cells were washed with 500ul of cell staining buffer from 
Biolegend® (San Diego, CA, USA) (product #: 420201) and spun down at 2500 RPM for 
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3minutes. Cells were resuspended in 100 µl of cell staining buffer prior to the addition of 
5 µl of either PE mouse IgG1, κ Isotype control Ab from Biolegend (product #: 400113, 
San Diego, CA, USA)) or PE anti-human CD156c (ADAM10) from Biolegend (product #: 
352703, San Diego, CA, USA)). The plate was incubated at 4°C for 15-20 minutes in 
the dark. After which the cells were washed twice with 500 µl of cell staining buffer, 
spun down at 2500 RPM for 3 minutes and resuspended in a final volume of 300ul prior 
to being analyzed by flow cytometry on a BD accuri C6 flow cytometer. 
Measurement of metalloprotease activity in cells treated with TAPI2: 
Metalloprotease activity was measured using the Mca-P-L-A-Q-A-V-Dpa-R-S-S-
S-R-NH2 Fluorogenic Peptide Substrate III from R&D systems. (Catalog #: ES003, 
Minneapolis, MN, USA) THP1 cells were resuspended at a concentration of 1 x106 
cells/ml in 25 mM Tris buffer at a pH 8.0 as per manufacturers protocol.  The assay was 
run in a 96 well plate in a 100 µL reaction with a final concentration of 10 µM of 
substrate per well. Reads were done every 2 minutes and TAPI2 100 µM or vehicle 
were added after 12 minutes and reads continued for 30 minutes. 
Purified ADAM10 activity assay: 
This assay was conducted using the SensoLyte® 520 ADAM10 Activity Assay 
from ANASPEC (Fremont, CA, USA) as per manufacturers protocol. (Catalog #: 72226) 
GI254023X was used a final concentration of 20 µM and TAPI2 100 µM. Reads were 
taken every five minutes for a total of 60 minutes. 
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2. Results: 
ADAM10 expression is required for α-hemolysin induced cell death in human 
monocyte-derived cells  
Previous work has shown ADAM10 to be important for the activity of α-hemolysin 
(Hla) towards a variety of host cell types [107, 130, 131]. Loss of expression of ADAM10 
using either siRNA in immortalized human epithelial cells or tissue specific genetic 
knock-out in mouse epithelial cells blocks Hla induced cell death [107]. Lung epithelium 
specific knock out of the ADAM10 gene protects mice from pulmonary injury induced by 
Hla inhalation or live S. aureus instillation [129]. Targeted deletion of ADAM10 in mouse 
myeloid cells also protects them from Hla induced death in a murine pneumonia model 
[127]. We sought to confirm that ADAM10 expression is required for human monocytic 
cell responsiveness to Hla. Monocytic THP1 cells were transfected with siRNA directed 
against ADAM10 (both individual siRNAs and pooled siRNA) and after three days cell 
surface expression was characterized by flow cytometry. We were able to achieve 
significant reductions in detectable cell surface expression of ADAM10 as compared to 
our non-targeting siRNA controls (Figure 2.1B-D). Immunoblot analysis also showed 
reductions of total ADAM10 (Figure 2.1E). Because it has previously been shown that 
NLRP3 expression is required for Hla-induced cell death in monocytes, siRNA directed 
to NLRP3 were used as a positive control. While siRNA directed to NLRP3 reduced 
NLRP3 expression levels, it had no effect on ADAM10 levels measured by flow 
cytometry or immunoblot (Figure 2.1C-E). siRNA transfected THP1 cells were then 
treated with Hla and cytolysis was subsequently assessed by measuring release of 
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cytosolic LDH into the culture supernatant. Depletion of NLRP3 or ADAM10 by siRNA 
significantly reduced Hla-induced LDH release as compared with controls. (Figure 2.1F) 
To demonstrate the effect of ADAM10 depletion was specific to Hla-induced cell death 
and not generally suppressive of NLRP3 activation, siRNA transfected cells were also 
treated with nigericin, a pore forming toxin known to activate NLRP3, and assessed for 
cell death [138]. As expected, NLRP3 depletion blocked nigericin-induced death while 
ADAM10 depletion had no effect. (Figure 2.1G) 
 
ADAM10 expression is required for Hla-mediated NLRP3 inflammasome 
activation in monocytes. 
Hla-induces inflammatory cell death by activating the NLRP3 inflammasome in 
monocytes [123]. Activation of the NLRP3 inflammasome leads to activation of the 
cysteine proteinase caspase-1 and subsequent processing and secretion of the 
cytokines IL-1β and IL-18 [133]. To determine whether ADAM10 is required for Hla-
mediated NLRP3 activation, THP1 cells transfected with individual siRNA directed 
against ADAM10 as well as pooled siRNA targeting ADAM10 and NLRP3 were 
challenged with α-hemolysin and IL-1β secretion by the cells as well as activation of 
caspase-1 were assessed. Cells depleted of ADAM10 expression using 4 different 
siRNA against ADAM10 all demonstrated a marked reduction in IL-1β secretion when 
compared to non-targeting control siRNA. (Figure 2.2A) Caspase-1 activation was 
assessed by accumulation of a fluorescent inhibitor of caspase-1 (caspase-1 FLICA) 
after toxin administration. Knockdown of ADAM10 or NLRP3 by pooled siRNA 
transfection of THP1 cells significantly decreased caspase-1 activation in response to 
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Hla (Figure 2.2B & 2.2C). Cells depleted of ADAM10 or NLRP3 expression by 
transfection of pooled siRNA exhibited markedly reduced release of IL-1β in response to 
Hla exposure. (Figure 2.2D) To test whether ADAM10 depletion effected NLRP3 
activation in general or only in response to Hla, siRNA-transfected cells were treated 
with nigericin or ATP, which activates NLRP3 through activation of the P2X7 purinergic 
receptor [139]. ADAM10 knockdown did not affect secretion of IL-1β after treatment with 
either ATP or nigericin. (Figure 2.2D) In contrast to the reductions in Hla-induced IL-1β 
secretion observed after transfection with NLRP3 or ADAM10 directed siRNA, secretion 
of MIP-1α, a cytokine that is not dependent on caspase-1 proteolysis for secretion, was 
not reduced at all in these cells relative to the control siRNA transfected cells. (Figure 
2.2E) Thus, ADAM10 expression is critical for NLRP3 activation by Hla but not by other 
NLRP3 activating stimuli. 
 
The protease activity of ADAM10 is not required for Hla-mediated activation of 
NLRP3-induced cell death. 
Chemical inhibition of ADAM10 using GI254023X, a specific inhibitor of ADAM10 
reduces Hla-mediated cytotoxicity and cleavage of extracellular E-cadherin in epithelial 
and endothelial cells [129, 131, 140]. To determine whether the protease activity of 
ADAM10 was required for Hla-induced NLRP3 activation, we treated cells with TAPI2, a 
non-specific metalloprotease inhibitor or GI254023X. THP1 cells were treated with 
inhibitor for 15-30 minutes prior to challenge with Hla.  Short-term treatment of THP1 
cells (15-30 min) with these inhibitors did not reduce Hla-induced cytotoxicity (Figure 
3A&B). Inoshima et al. demonstrated that treatment of epithelial cells with GI254023X 
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led to diminished ADAM10-mediated E-cadherin cleavage within minutes of addition of 
the inhibitor [10]. To ensure short-term treatment with ADAM10 inhibitors could 
suppress protease activity in the 30 min time-frame of our experiments, we tested the 
effect of the inhibitors on measurable protease activity. We found that TAPI2 and 
GI254023X were able to immediately impact the rate of peptide substrate cleavage by 
purified ADAM10 (Figure 2.3C). Further, total metalloproteinase activity in intact THP1 
cells was immediately diminished by the addition of TAPI2 (Figure 2.3D). Combined 
these results demonstrate that the proteinase activity of ADAM10 is not required α-
hemolysin-induced cell death.  
 
Inhibitors of ADAM10 protease activity reduce Hla-mediated activation of the 
NLRP3 inflammasome through down regulation of surface ADAM10 levels. 
In contrast to the findings with short-term inhibition of ADAM10, overnight 
treatment with GI254023X diminished Hla-mediated but not nigericin-induced 
cytotoxicity in THP1 cells. (Figure 2.4A).  Overnight treatment with TAPI2, also caused a 
downward trend in Hla-induced death, though this did not meet statistical significance. 
(Figure 2.4B) Overnight treatment with TAPI2 or GI254023X inhibited Hla-induced IL-1β 
secretion but not nigericin-induced IL-1β secretion in THP1 cells while 30 minute 
inhibitor treatment had no effect on IL-1β secretion (Figure 2.4C-F) because inhibition of 
ADAM10 protease activity did not immediately diminish Hla-induced NLRP3 
inflammasome activation, we tested whether prolonged inhibitor treatment altered 
NLRP3 expression levels using immunoblot analysis. Levels of NLRP3 were not altered 
by treatment of THP1 cells with GI254023X for 20 hours (Figure 2.5A), consistent with 
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the continued response of these cells to nigericin (Figure 2.4D&F). We then sought to 
determine whether chemical inhibition altered the quantity of surface expressed 
ADAM10.  Treatment of THP1 cells with either inhibitor for 30 minutes had no significant 
effect on cell surface expression of ADAM10 detectable by flow cytometry. After 20 
hours, treated THP1 exhibited diminished detectable surface ADAM10. (Figure 2.5A, B 
& C) To better understand the time dependent difference in the response of THP1 cells 
treated with these inhibitors, we assessed the ADAM10 cell surface expression over 
time during treatment with GI254023X using flow cytometry. Cell surface expression of 
ADAM10 decreased over time when compared to vehicle treated cells. As expected, the 
loss of ADAM10 expression was accompanied by similar reductions in Hla-induced IL-
1β secretion at the corresponding timepoints in THP1 cells. (Figure 2.5 D & E) To 
ensure the effects of ADAM10 inhibition on ADAM10 cell surface expression and Hla-
induced IL-1β was not limited to THP1 cells, we tested whether prolonged GI254023X 
exposure in U937 cells had an effect on ADAM10 levels and IL-1β secretion. U937 cells 
treated with GI254023X replicated the effects observed with THP1 cells. (Figure 2.6) 
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Discussion: 
ADAM10 is important for α-hemolysin binding to target cells [107]. In addition, 
Hla binding leads to increased ADAM10 proteolytic activity in keratinocytes, endothelial 
cells, and epithelial cells [107, 129-131]. This increased activity leads to disruption in 
cell-to-cell contacts through cleavage of E-cadherin and plays a key role in S. aureus 
pathogenesis. In addition to causing disruption of cell-to-cell contacts, Hla is known to 
induce potent pro-inflammatory signals in myeloid cells, including the production of IL-
1β and induction of programmed necrotic cell death [123]. These pro-inflammatory 
actions of Hla require host cell NLRP3 inflammasome activity [123]. Targeted deletion of 
ADAM10 in myeloid cells results in diminished lung levels of IL-1β in a mouse model of 
S. aureus pneumonia [13]. In a S. aureus sepsis model, elimination of ADAM10 from 
platelets and myeloid lineages resulted in diminished IL-1β observed in liver 
homogenates, decreased lung and liver pathology, and decreased mortality in mice 
[132]. We have now shown that ADAM10 is required for Hla to activate the NLRP3 
inflammasome in human monocytes (Figure 2.2).  Our data suggest that the diminished 
tissue levels of IL-1β observed in these mouse models lacking ADAM10 are the direct 
result of diminished inflammasome activation in myeloid cells from the infected animals. 
Interestingly, loss of ADAM10 has also been implicated in lung epithelial injury from 
other bacterial pore-forming toxins, like pneumolysin from Streptococcus pneumonia 
[129]. We have demonstrated that myeloid cell ADAM10 is not required for NLRP3 
activation by nigericin, a second pore-forming toxin. The difference in ADAM10 
requirement for cellular injury between epithelial cells and monocytic cells in response 
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to pore-forming toxins other than Hla may have to do with role of ADAM10 proteolytic 
activation in those cell types. 
In mice, ADAM10 inhibitors prevent the loss epithelial barrier integrity that is 
typically induced by S. aureus Hla during infections of the skin and lung [129, 130]. The 
enhancement of ADAM10 proteolytic activity by Hla is clearly tied to that aspect of 
infection pathogenesis, which is likely important for the bacteria to establish invasive 
infection of the tissues the toxin is acting on. However, in published studies of S. aureus 
infection in mice lacking ADAM10 in myeloid lineage cells, the role of ADAM10 
proteolytic activity, as opposed to high affinity Hla-binding remains unknown. Our data 
now demonstrate that ADAM10 proteolytic activity is not required for host 
inflammasome activation in isolated immune cells.  Because inhibitors of ADAM10 
proteolytic activity ultimately result in reduced levels of myeloid cell surface expression 
of ADAM10, these inhibitors can still reduce Hla-induced inflammasome activation. 
These data suggest that in myeloid cells ADAM10-facilitated targeting of Hla to the cell 
is sufficient for NLRP3 inflammasome activation, which leads to both IL-1β secretion 
and cell death. The exact mechanism by which these inhibitors lower ADAM10 cell 
surface expression remains to be explored.  ADAM some family members are known to 
undergo autoproteolysis, it is possible that processing is important for maturation and/or 
proper trafficking of ADAM10 [141]. Although we have not demonstrated that 
pharmacologic ADAM10 inhibition reduces cell surface ADAM10 expression on other 
cell types, our findings open the possibility that ADAM10 inhibitors may improve 
outcomes in murine S. aureus infection models through multiple mechanisms including 
both reduction in ADAM10-mediated adherence factor cleavage and reduction of Hla-
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receptor on multiple cell types. Further, the mechanisms by which Hla activates NLRP3 
remain to be elucidated but are also still potentially attractive therapeutic targets for 
adjunctive therapy to antibiotic therapy in severe S. aureus infections. 
In mouse models, the consequences of the loss of Hla activity towards myeloid 
cells differs based on the location of infection.  The loss of ADAM10 in the immune cell 
compartment or global loss of NLRP3 was beneficial to the host in a mouse pneumonia 
model of S. aureus infection, reducing mortality compared to mice with intact ADAM10 
or NLRP3 [127]. Loss of ADAM10 from the myeloid lineage is deleterious to the host in 
the skin infection model of mouse staphylococcal disease by leading to increased lesion 
size and bacterial burden [127]. Prior studies by our group and others have tied Hla-
induced inflammasome activation to worsened host outcomes in S. aureus infections 
[124]. Genetic deletion of NLRP3 improved clinical parameters in mouse pneumonia 
without effecting pathogen burden, suggesting that blunting the inflammasome 
mediated inflammatory response to S. aureus could be beneficial even after infection is 
established [124]. This combination of findings suggested that inhibition of ADAM10 
could be an attractive mechanism to reduce deleterious effects of robust inflammatory 
response during severe S. aureus infection. Because the effects of Hla on myeloid 
derived human cells is likely redundant to several other pore-forming, immune cell-
restricted toxins, known as leukotoxins, made by S. aureus, the role of Hla activity on 
immune cells in human infection is unknown. Like Hla, these leukotoxins also activate 
the NLRP3 inflammasome [137, 142]. Thus, during S. aureus infection, the host 
inflammasome will be activated in immune cells regardless of the interaction between 
ADAM10 and Hla. The role of the NLRP3 inflammasome in mediating Hla effects on 
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non-immune cells remains another open question in the field. Several studies have 
shown Hla antibody titers are important predictors of disease outcome in patients with 
S. aureus infections [143, 144]. Gaining a better understanding of how Hla specifically 
contributes to human disease by targeting leukocytes and other cell types will be an 
important step in the development of novel, specific therapies for Staphylococcal 
disease. 
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Figure 2.1: (A) Histogram showing staining with ADAM10-directed antibody compared 
to isotype control measured by flow cytometry. (B-D) THP1 cells were transfected with 
the indicated siRNA three days prior to assessing ADAM10 cell surface expression via 
flow cytometry, as detailed in the experimental methods section and demonstrated in A.  
(B) The relative surface expressed ADAM10 mean fluorescence intensity of THP1 cells 
transfected with 4 different siRNA targeting ADAM10 as compared to the non-targeting 
control siRNA transfected cells. (C) Histogram showing fluorescence intensity of 
ADAM10 staining between cells transfected with non-targeting siRNA and siRNA pools 
targeting Lamin, NLRP3, and ADAM10. (D) The relative surface expressed ADAM10 
mean fluorescence intensity of siRNA pool transfected THP1 cells as compared to the 
non-targeting control. For both B and D, n=3. (E) Whole cell lysates from cells 
transfected with the indicated siRNA pools were analyzed by immunoblot analysis with 
antibodies for ADAM10, NLRP3, and Actin as a loading control. (F&G) siRNA-
transfected THP1 cells were treated with α-hemolysin (Hla) (30 µg/mL) or Nigericin 
(Nig) (50 µM) for 1 hour. Culture supernatants from untreated and toxin-treated cells 
were assayed for LDH production as compared to a detergent-lysis control (n=3). For 
B&D, **** indicates statistically significant difference from Non-Tg transfected cells (p≤ 
.0001) determined by one-way ANOVA with Dunnett’s multiple comparisons testing. For 
F&G, ** and *** indicates statistically significant difference from Non-Tg transfected cells 
(p≤.01 and p≤.001 respectively) determined by two-way ANOVA testing with Dunnett’s 
multiple comparison testing. 
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Figure 2.2: THP1 cells were treated with the indicated siRNA three days prior to 
assessment, as in Fig 2.1. siRNA-transfected THP1 cells were treated with LPS 
(100ng/mL) for 3 hours before the addition of an NLRP3 simulating agent for 1 hour. 
Cell culture supernatants were then assayed for cytokine production. For some analysis 
the relative secretion of cytokine as compared with toxin-treated, non-targeting siRNA-
transfected control cells is plotted. A) Absolute (top) and relative (bottom) IL-1β 
secretion in hemolysin treated THP1 cells transfected with individual ADAM10 siRNAs 
(n=3). (B) THP1 cells transfected with the indicated siRNA pool were treated with 
Caspase-1 FLICA reagent prior to the addition of α-hemolysin (30 µg/ml) for 30 minutes. 
Cells are then washed, fixed and assayed by flow cytometry. Representative histograms 
showing caspase-1 FLICA reagent based fluorescence in resting (left) and α-hemolysin-
treated (right) cells previously transfected with the indicated siRNA. (C) Caspase-1 
FLICA activation mean fluorescence intensity in cells treated with hemolysin (30 µg/mL) 
(n=3). (D) Relative IL-1β secretion as compared with non-targeting control in cells 
treated with α-hemolysin (30 µg/mL) (n=7) top, ATP (5 mM) (n=4) middle, and nigericin 
(50 µM) (n=3) bottom.  (E) Relative MIP1-α secretion as compared with non-targeting 
control in cells treated with hemolysin (30 µg/ml) (n=3) or nigericin (50 µM) (n=3).  
For (A & D) ** & **** indicates statistically significant difference from Non-Tg (p≤.01 and 
p≤ .0001, respectively) determined by one-way ANOVA with Dunnett’s multiple 
comparisons testing. For (C) ** Indicates statistically significant difference between no 
treatment and Hla treatment (p≤ .01) determined by one-way ANOVA with Sidak’s 
multiple comparison testing.  
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Figure 2.3: (A&B) THP1 cells were incubated with either GI254023x (20 µM) or TAPI2 
(100 µM) inhibitors or inhibitor vehicle (DMSO for GI254023X or H2O for TAPI2) for 30 
minutes, propidium iodide (PI) was then added to the cells followed by treatment with 
either nothing (untreated, n=3), α-hemolysin (30 µg/mL) (Hla, n=3), or nigericin (50 µM) 
(Nig, n=3) for 1 hour. Cell death was assessed by measuring cells that stained positive 
for PI using flow cytometry.  (C) Purified recombinant ADAM10 protein was mixed with 
vehicle (square), 20µM GI254023X (upward triangle) or 100µM TAPI2 (downward 
triangle) and immediately assayed for ADAM10 protease activity as described in the 
Materials and Methods for 60 minutes with measurements taken every five minutes. (D) 
Metalloprotease activity was measured in THP1 cells by incubating intact cells with a 
fluorogenic peptide substrate and measuring fluorescent intensity every 2 min. After 10 
min, the metalloproteinase inhibitor TAPI2 (100µM) or vehicle was added to the reaction 
and fluorescence intensity was measured an additional 30 min. 
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Figure 2.4: (A&B) THP1 cells were incubated with either GI254023x (20 µM) or TAPI2 
(100 µM) inhibitors or inhibitor vehicle (DMSO for GI254023X or H20 for TAPI2) for 20 
hours, propidium iodide (PI) was then added to the cells followed by treatment with 
either nothing (untreated, n=3), α-hemolysin (Hla, n=3), or nigericin (Nig, n=3) for 1 
hour.  (C-F) THP1 cells were incubated with the indicated inhibitors either overnight (20 
hours) or for 30 minutes. Cells were subsequently incubated with LPS (100 ng/mL) for 3 
hours followed by no addition (untreated, n=3), α-hemolysin (30 µg/mL) (Hla, n=3), or 
nigericin (50 µM) (Nig, n=3) for one hour. Cell-culture supernatants were then collected 
and assayed for IL-1β. Results are reported as either relative secretion to secretion from 
vehicle exposed cells subsequently treated with the indicated toxin (Hla or Nig). * & *** 
indicates statistically significant difference from vehicle treated cells intoxicated with Hla 
(p≤ .05 or p≤ .001, respectively) determined by one-way ANOVA with Dunnett’s multiple 
comparisons testing. 
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Figure 2.5: (A) Cells were treated with either vehicle (DMSO) or GI254023X  
(20 µM) for 20 hours and cell lysates were analyzed by immunoblot for NLRP3 and 
Actin (loading control) as indicated. Lysates from three separate vehicle treated cell 
populations and three separate GI254023X-treated cell populations were tested. (B) 
Representative histograms showing the cell surface staining in vehicle- or ADAM10 
inhibitor-treated THP1 cells at either 0 or 20 hours of inhibitor treatment. (C) THP1 cells 
were treated with GI254023X (20 µM), TAPI2 (100 µM), or vehicle overnight or 15-30 
minutes before flow cytometric analysis of ADAM10 cell surface expression. Each bar 
represents the mean of the mean fluorescent intensity of cell surface staining from 
multiple experiments (n=3)  (D-F) THP1 cells were treated with GI254023X (20 µM) or 
DMSO for 0, 3, 6 hours, or overnight before flow cytometric analysis of ADAM10 cell 
surface expression or treatment with α-hemolysin (30 µg/mL) was carried out as above. 
(n=3) For (C), *** and **** Indicates statistically significant reduction when compared to 
vehicle-treated controls (p ≤ .001 and p ≤0.0001, respectively) determined by one-way 
ANOVA with Dunnett’s multiple comparisons testing. For (D&E), **** Indicates 
statistically significant reduction when compared to vehicle treated control at the same 
time point (p≤ .0001) determined by two-way ANOVA with Sadik’s multiple comparisons 
testing.  
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Figure 2.6:(A) U937 cells were treated with GI254023X (20 µM) or vehicle for 20 hours 
and ADAM10 cell surface expression measured. (B) PMA-differentiated U937 cells were 
treated with GI254023X (20 µM) or vehicle for 20 hours prior to treatment with α-
hemolysin (10 µg/mL). For (A) *** Indicates statistically significant reduction when 
compared to vehicle treatment (p≤ .0001) determined by paired T-test. For (B) **** 
Indicates statistically significant when compared to vehicle treated control cells (p≤ 
.0001) determined by one-way ANOVA with Sadik’s multiple comparisons testing. 
 		 44	
 
 
 
 
 
Fig 2.7 Graphical Abstract 
 
  
A
D
A
M
10
* 
A
D
A
M
10
 
NLRP3 Inflammasome 
Active 
Caspase-1  
activation 
Inflammatory cell 
death 
IL-1β 
IL-18 
Protease activity not required for 
inflammasome activation 
Inactive 
S. aureus  
Hla-receptor activity required 
for inflammasome activation 
Hla 
 		 45	
 
CHAPTER THREE: α-hemolysin-mediated activation of the NLRP3 Inflammasome 
in Primary Human Airway Epithelial cells 
 
 
Introduction:  
Staphylococcus aureus can cause serious respiratory tract infection including 
infection of the airways (bronchitis or bronchiolitis) and the alveoli (pneumonia). S. 
aureus can cause necrotizing infections of the lungs characterized by severe localized 
inflammation, leading to high morbidity and mortality [82, 84]. The high mortality of 
these conditions in the face of antibiotic therapy demonstrates a need to understand the 
pathogenesis of these infections in order to develop therapies that prevent the 
development of infection (vaccination) or that can mitigate the severity of established 
infections. The bacterium is known to produce several virulence factors including α-
hemolysin (Hla), which are important for pulmonary pathogenesis [45, 46, 57]. Unlike 
many S. aureus pore forming toxins, Hla can act on both epithelial cells and immune 
cells in the lung [86]. Hla is a soluble monomeric protein that once secreted by the 
bacterium forms a heptameric pore in a broad range of host cell membranes [94, 104]. 
Additionally, Hla is a critical virulence factor in murine models of staphylococcal 
infection and has being implicated in human disease [111, 112, 115, 131, 143, 144]. A 
Disintegrin and Metalloprotease 10 (ADAM10) acts as a cellular receptor for Hla [107]. 
Knockdown of ADAM10 protects immortalized human epithelial cell cultures from Hla-
induced death [107]. Genetic deletion of ADAM10 in the lung epithelium using a Cre 
 		 46	
recombinase driven by the surfactant protein C promoter or chemical inhibition of the 
protein, mitigates Hla-induced pathology and makes animals resistant to lethal 
pneumonia in mouse models of disease [129]. Additionally, in epithelial and endothelial 
cells, Hla has been shown to increase the protease activity of ADAM10 leading to 
cleavage of cellular adherence factors like E-cadherin [107, 130].  
Hla also potently activates the host signaling complex known as the Nucleotide-
binding domain and Leucine-Rich repeat containing family Pyrin domain containing 3 
(NLRP3) inflammasome in monocytes [123, 124]. The NLRP3 inflammasome is an 
important innate immune signaling complex that is part of a large collection of host 
signaling moieties that are responsible for sensing and responding to microbial threats. 
The NLRP3 inflammasome, once activated, forms a protein complex comprised of 
NLRP3, apoptosis-associated speck-like protein (ASC), and pro-caspase-1. The 
inflammasome converts pro-caspase-1 into the proteolytically active caspase-1 enzyme 
that cleaves the precursors of IL-1β and IL-18 into their active forms. Additionally, 
inflammasome activation induces a pro-inflammatory program of cell death 
characterized by the morphologic features of necrosis [134-136]. In a murine model of 
Hla intoxication during S. aureus infection genetic loss of NLRP3 was seen to be 
beneficial for both survival and immune-mediated damaged by the toxin [124].  
Primary airway epithelial cells also express a functional NLRP3 inflammasome 
that can be activated by particulate matter and Influenza A virus infection [145, 146]. 
Primary airway epithelial cells can be prepared from nasal turbinate, trachea and 
bronchi from human donor airways. The tissue is dissected and dissociated using 
proteases. Cells are then scraped from the epithelial surface and plated directly onto 
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porous support for the production of ALI (Air-liquid interface) cultures or are plated on 
collagen-coated tissue cultures plates using Bronchial epithelial growth medium 
(BEGM) or ALI growth media or ALI cell as defined here by Fulcher et al [147]. Cells 
grown on tissue culture treated plates assume a squamous, poorly-differentiated 
phenotype while ALI cultures assume a fully polarized architecture reminiscent of the 
normal intact airway [147].  ALI cells differentiate into both secretory and ciliated cells, 
make and move mucus by ciliary action, and are capable of being infected by airway 
specific pathogens like RSV (Respiratory Syncytial Virus) [147-150]. In work conducted 
by Hirota et al., these primary airway epithelial cells were found to express the 
inflammasome components NLRP3, caspase-1, and IL-1β by both In situ staining of 
cross sections of human bronchus and immunoblot analysis of primary human airway 
epithelial (hAE) cells. Primary hAE cells also secrete IL-1β and show evidence of 
caspase-1 cleavage in response to urban particulate matter treatment [145]. Hirota and 
colleagues were able to reverse particulate matter induced IL-1beta secretion by 
treating the hAE cells with siRNA against NLRP3. Allen et al. also showed strong 
induction of IL-1β secretion in primary hAE grown in ALI cultures in response to 
influenza infection [146].   
In this chapter, we have begun to address the hypothesis that NLRP3 
inflammasome signaling is activated by S. aureus α-hemolysin in respiratory epithelium 
and that this signaling is an important factor in inflammatory signaling in the respiratory 
tract. 
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Methods and Materials: 
Treatment of cultured cells with α-hemolysin for cytokine studies: 
Human primary airway epithelial were harvested and grown as review here [147, 
151]. Prior to treatment, hAE cells grown in plastic tissue culture treated plates were 
washed and media changed. Cells were then treated with 1 µg/ml of lipoteichoic acid for 
24 hours after which media was again collected and fresh media added. Cells were then 
treated with Hla (100 µg/ml) and supernatants collected after either 4 or 24 hours of 
intoxication and all supernatants were collected by centrifugation at 13000 RPM for 3 
minutes. Cell culture supernatants were stored frozen at -80°C until assayed for 
cytokine production. IL-1β was measured using BD bioscience (product #: 557953, San 
Jose, CA, USA) ELISA kits as per manufacturer protocols. Recombinant α-hemolysin 
was prepared as described by Craven et al [123]. 
For cells grown in the Air-liquid interface format, one day prior to that start of 
treatment cells are washed and fed fresh media. The next day samples were collected 
from both the apical and basolateral sides of the culture. The cells were then washed 
and fresh media is added. Cells were subsequently challenged apically with 20% 
pseudomonas aeruginosa culture filtrates in media for 24 hours prior to challenge with 
Hla. Samples were collected the next day from both the apical and basolateral sides of 
the culture, cells were washed and fresh media added to cultures. Cells were then 
challenged apically with 50 µl of media containing the 50 µg/ml of Hla for 24 hours. 
Supernatant were again collected both apically and basolaterally and all supernatants 
were centrifuged at 13000 RPM for 3 minutes. Supernatants were stored frozen at -
80°C until assayed for cytokine production. IL-1β was measured using BD bioscience 
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(product #: 557953, San Jose, CA, USA) ELISA kits as per manufacturer protocols. We 
used cells grown for 3 days at ALI and fully differentiated ALI cultures grown for over 21 
days (used on day 35).  
 
Treatment of cultured cells with α-hemolysin for cell death studies: 
Human primary airway epithelial were harvested and grown as detailed in this 
review [147, 151]. Prior to treatment hAE cells grown on plastic were washed and media 
changed. Cells were then treated with 1 µg/ml of lipoteichoic acid for 24 hours after 
which media was again collected and fresh media added. Cells were then treated with 
Hla (100 µg/ml) and supernatants collected after either 4 or 24 hours of intoxication. 
Cells and supernatants were collected by centrifugation at 13000 RPM for 3 minutes. 
Prior to the end of the experiment a control group of cells were lysed using 1% Triton X-
100 as a lysis control. Cell culture supernatants were stored frozen at -80°C until 
assayed for LDH production. LDH was measured using the CytoTox-ONE 
Homogeneous Membrane Integrity Assay from Promega (product #: 557953, Madison, 
WI, USA) as per manufacture protocols. 
Caspase-1 activity was measured using the FAM-FLICA® caspase-1 assay kit, 
far-red fluorescence (Product #:97) from ImmunoChemistry Technologies LLC 
(Bloomington, MN, USA). hAE cells were plated on glass chamber slips and allowed to 
grow overnight. The FLICA reagent was added and incubated with cells for 5 minutes 
prior to the addition of α-hemolysin for one hour. Cells were washed once using 1x 
FAM-FLICA® caspase-1 assay kit wash buffer after which 1 µg/ml Hoeschst 3334L from 
caspase-1 kit in 500uL total volume was added to each slip. Cells were further stained 
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for 10 minutes before being washed twice with wash buffer. Cells were resuspended in 
1ml of PBS containing FAM-FLICA® caspase-1 assay kit fixative diluted 1:10. 
Accumulation of fluorescent caspase-1 inhibitor was assayed by microcopy using a 
EVOS Cell imaging system by ThermoFisher (Waltham, MA. USA). 
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Results: 
Primary human airway epithelial cells grown on collagen treated tissue culture 
plates show makers of inflammasome activation in response to treatment with α-
hemolysin. 
To begin to test whether the NLRP3 inflammasome plays a role in airway 
epithelial responses to S. aureus hemolysin, we tested whether primary epithelial cells 
died, activated caspase-1 and produced IL-1β in response to Hla treatment. Primary 
human airway epithelial cells were grown to confluence in tissue culture treated plates 
prior to challenge with Hla. 24 hours prior to challenge with Hla, we treated cells with 
lipoteichoic acid to promote the production of pro-IL-1β via TRL2 stimulation and NFκB 
signaling. Cells were then challenged with Hla and supernatants collected at either 4 or 
24 hours for measurement of cytokine production and cell death via LDH release. Cells 
treated with Hla showed higher secretion of IL-1β and cell death than untreated cells 
especially at 24 hours after toxin addition (Figure 3.1 A&B).  Next to test whether 
treatment of hAE with Hla leads to detectable levels of caspase-1 activation, we stained 
cells with Caspase-1 FLICA, which irreversibly binds to active caspase-1 enzyme. Upon 
binding the FLICA reagent fluoresces and we are able to wash out unbound reagent 
and detect caspase-1 activation via fluorescence microscopy. Cells were pretreated 
with FLICA reagent and then challenged with Hla for one hour. We then washed, fixed, 
and imaged the cells. In Hla-treated cells we were able to detect a strong fluorescence 
signal indicative of caspase-1 activation in the Hla treated population. (Figure 3.1C) 
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Primary human airway epithelial cells grown at air liquid interface produce IL-1β 
secretion in response to treatment with α-hemolysin. 
hAE cells grown at grown with an Air-liquid interface (ALI) provide an excellent 
model for studying the cells of the human airway as they mimic the morphology and 
variety of cell types seen in the human airway [147]. To determine if these cells were 
able to secrete IL-1β in response to challenge with Hla, we used two sets of ALI 
cultures. One culture that has been grown for at least 21 days which is considered full 
maturity and another ALI culture grown for 3 three day prior to treatment. The three-day 
culture mimics a less mature and more pro-inflammatory airway as marked by higher 
levels of baseline IL-8 production. Cells were treated with Pseudomonas aeruginosa 
culture filtrate 24 hours prior to Hla challenge to promote immune activation because 
previous work has shown the Pseudomonas culture filtrates to promote Toll-like 
receptor signaling in ALI cultures[152]. Cells were then challenged with Hla and after 24 
hours supernatants collected to assay for cytokine production. Hla treatment simulated 
IL-1β production from both sets of cultures with the Day 3 culture secreting higher levels 
of cytokine. (Figure 3.2)  
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Discussion: 
hAE cells are known to express NLRP3 inflammasome components. hAE cells 
are also capable of secreting IL-1β in response to challenge with Influenza A or 
particulate matter. We now have evidence that α-hemolysin treatment also leads to 
secretion of IL-1β in hAE cultures grown on collagen treated tissue culture plates and at 
ALI. Treatment with Hla also leads to the activation of caspase-1 as measured by FAM 
FLICA. These findings point to a possible role for the NLRP3 inflammasome in 
mediating Hla-induced pathogenesis in these cells. We currently know the importance 
of ADAM10 and its activity in mediating Hla effects in epithelial cells but NLRP3’s role 
has yet to be thoroughly investigated. NLRP3 activation and secretion of IL-1β, a 
powerful inflammatory cytokine, from these cell types could have important implications 
in mediating early inflammatory events in the course of S. aureus infection. These cells 
are the first to be encountered by the bacterium during infection and their ability to 
secrete inflammatory cytokines could be critical in the early immune response to the 
bacterium. 
In our model, day 3 ALI culture intoxication with Hla led to higher levels of IL-1β 
secretion and presumably inflammasome activation. If indeed the day 3 cultures 
represent more a proinflammatory cellular environment than their day 21 counterparts, 
this may provide evidence as to why the injured inflamed lung is more susceptible to 
bacteria infections that lead to severe disease. This can be observed keenly in the case 
of influenza and Staphylococcus aureus superinfection. In both human disease and 
animal models, influenza immediately followed by a S. aureus infection leads to more 
severe disease than either infection alone [153-155]. Our lab has previously shown that 
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in the setting of S. aureus pneumonia, NLRP3 activation is harmful and leads to 
increase mortality in mouse model of disease [124] and influenza infection simulates 
NLRP3 and release of IL-1β from these cells [143], so this hyper-activation of the 
inflammasome could further worsen disease outcomes.  
As this project is in its early stages, there are several lines of investigation I 
would like to follow up in the future. Using siRNA and/or viral RNAi delivery, I would like 
to knockdown key inflammasome components such as NLRP3, ASC, and caspase-1 to 
determine their roles in mediating the IL-1β secretion and cell death, we observe in hAE 
cultures. I would also like to determine using a super-infection model with influenza, 
what role NLRP3 activation in the airway epithelium may have in the increased 
pathology seen in this setting [80, 154, 155].  
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Figure 3.1: A&B) Primary human airway epithelial cells were challenged with 1 µg/ml of 
lipoteichoic acid for 24 hours after which cell were treated with 100 µg/ml of Hla. 
Supernatants were collected at either 4 or 24 hours after toxin treatment and assayed 
for IL-1β production and LDH release. C) Primary human airway epithelial cells were 
grown on glass chamber slide and treated with Caspase-1 FLICA, washed and 
challenged with 100ug/ml of Hla for one hour. Cell were then washed and the nuclei 
counterstained before imaging by Fluorescence microscopy. 
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Figure 3.2: Primary epithelial cells grown at air-liquid interface for either 3 or 35 days. 
The cells were washed and then challenged with 20% Pseudomonas aeruginosa culture 
filtrate in media for 24 hours prior to Hla challenge. Cell were challenge with 50 µg/ml of 
Hla apical and after 24 hours samples were collected from both the apical and 
basolateral sides of the cultures and assayed for IL-1β production.
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CHAPTER FOUR: Significance and Future directions 
 
In the outlined studies, we explored the mechanisms by which the ADAM10-
NLRP3 inflammasome signaling axis is required for S. aureus-mediated pathogenesis in 
monocytes and primary human epithelial cells. In chapter Two, we explored the role of 
ADAM10 in Hla-mediated activation of the NLRP3 inflammasome in human monocytes. 
ADAM10 is the cell surface receptor for Hla and loss of ADAM10 diminishes the ability 
of Hla to bind and intoxicate target cells [86, 107, 111, 127, 129-132]. Hla binding to 
ADAM10 also elicits increased protease activity in both epithelial [107, 129, 130] and 
endothelial cells [131]. This enhanced ADAM10 protease activity leads to disruption of 
cell-to cell contact and presumably break down of the epithelial/endothelial barrier. 
Interestingly, in models of S. aureus pneumonia and skin infection, specific ADAM10 
knockout in cells of myeloid origin recapitulated the effects seen in previous NLRP3 
knockout mouse models [124, 126, 127].  But the specific role of ADAM10 and its 
protease activity in NLRP3 inflammasome activity had not been explored. We have 
demonstrated that ADAM10’s ability to serve as a cell surface receptor for hemolysin 
and not its protease activity is important for facilitating Hla-mediated NLRP3 
inflammasome activation. siRNA knockdown and chemical blockade of the ADAM10 
leads to diminished α-hemolysin-mediated inflammasome activation. This was due to 
the reduction in ADAM10 cell surface expression caused by both RNAi treatment and 
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prolonged inhibitor exposure. This latter finding is especially novel as treatment with 
ADAM10 chemical inhibitors not only inhibited protease activity but also decreased 
ADAM10 cell surface expression in a time dependent fashion, which to my knowledge 
has not been previously reported.  
There are a number of questions that arise from this work that would warrant 
further study. First, I would like to determine the mechanisms behind the inhibitor-
mediated suppression of ADAM10 cell surface expression. There is a possibility that 
ADAM10 proteolysis is being blocked leading to improper trafficking and maturation of 
the protein [141]. Another question that arises is whether inhibitor-mediated suppression 
of ADAM10 cell surface expression is specific to cells of myeloid origin or is a general 
mechanism by which long-term inhibitor treatment affects all cell types that express 
ADAM10. This has implications because in animal models where the ADAM10 inhibitor 
GI254023X was shown to reduce mortality from S. aureus infection, it was presumed 
that inhibitor either blocked Hla binding or that the blockade of ADAM10 protease 
function was what conferred the better outcomes [129-131]. Our works points to the 
suppression of ADAM10 cell surface expression as the mechanism by which this 
inhibitor reduces Hla-mediated pathology by the bacterium in-vivo. Finally, the exact 
mechanism by which Hla activates the NLRP3 inflammasome down stream of ADAM10 
has yet to be determined. We know from prior work in the lab that high extracellular K+ 
can diminish Hla-mediated inflammasome activation but the deeper mechanism behind 
this have yet to be explored. One possible mechanism downstream of this that could 
bridge the gap is ROS and the generation of oxidized mitochondrial DNA. There is 
evidence that oxidized mitochondrial DNA may play an important role as a downstream 
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activation step for NLRP3 activation as it has been shown to be important for both ATP 
and nigericin-mediated NLRP3 inflammasome activation in macrophages [39]. 
These studies help to clarify the role of ADAM10 in hemolysin-mediated 
pathogenesis in monocytes, illustrating cell-type specific differences in Hla-ADAM10-
mediated pathology. Pointing to a promising future for ADAM10 inhibitors as potential 
treatments to not only protect patient’s epithelial/endothelial cell barrier integrity but to 
also reduce hemolysin-mediated immune activation in the context of S. aureus infection.  
In Chapter Three, we sought to determine the role of NLRP3 signaling in 
mediating α-hemolysin-induced pathogenesis in epithelial cells. These cells are the first 
line of defense in maintaining airway integrity in S. aureus infections and often directly 
encounter pathogens. Primary human epithelial cells express inflammasome 
components and secrete IL-1β in response to particulate matter [145] and influenza 
infection[146]. Epithelial cells express ADAM10 and are sensitive to Hla intoxication 
leading to disruption of cell-to-cell contacts and cell death [107, 129] in cultured cells 
and animal models of disease. While the role of ADAM10 in hemolysin-mediated 
pathogenesis is well elucidated in epithelial cells, the functions of NLRP3 in mediating 
hemolysin pathogenesis in epithelial cells are unknown. Using a primary human airway 
epithelial cell model we sought to shed some light on the role of NLRP3 in this process. 
We were able to show strong evidence of NLRP3 activation in this model with hAE cells 
grown both with traditional cell culture methods on collagen coated plates and at air-
liquid interface. With ALI cultures being the better model of well-differentiated airway 
epithelium with both secretory and ciliated cells types present [147, 151]. Both cells 
grown at air-liquid interface and on traditional cell culture plates secreted IL-1β in 
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response to hemolysin intoxication and we were able to detect caspase-1 activation via 
caspase-1 FLICA staining in response to hemolysin treatment. These studies point to 
inflammasome activation being present in hemolysin treated hAE and a possible role for 
this activation in mediating hla-induced pathogenesis.  
This project is still in its early stages and there is much left to pursue. We would 
like to determine whether the IL-1β is being generated in a NLRP3 dependent or if some 
other inflammasome may be responsible. We would like to begin by knocking down a 
number of inflammasome components including NLRP3, ASC and caspase-1 in hAE 
cells to determine what role if any they play in this process. This can be readily done 
with cells grown on collagen plates, which are more readily transfected. We also know 
from both animal models of infection and in studies of human patients that influenza 
followed by bacterial super-infection leads to worse outcomes and severe disease [154, 
155]. In addition, we know that influenza infection can stimulate IL-1β production in an 
NLRP3 dependent manner in these cell types [146]. So in order to follow up on this 
finding we would like to develop an influenza/S. aureus super infection model to 
determine if NLRP3 or more broadly inflammasome activation has a more profound 
effect on influenza infected cells in the context of hemolysin intoxication. The studies 
outlined in this thesis help to delineate the role of NLRP3 in S. aureus α-hemolysin-
mediated immune activation in both monocytes and epithelial cells. This is an important 
step in furthering our understanding of the complex interactions of α-hemolysin and by 
extension Staphylococcus aureus with different cell types.  
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Gaining a better understanding of the cellular dynamics involved in S. aureus 
pathogenesis gives us the best chance to develop new therapeutics to combat this 
deadly disease as antibiotic resistance continues to spread. 
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